Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mel-Vel: Bortezomib and Melphalan Conditioning in Multiple Myeloma
NCT00784823Phase 2Completed
- Sponsor
- Hackensack Meridian Health
- Start
- Jan 2007
- Primary completion
- Dec 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (4 arms), sponsored by Hackensack Meridian Health. Primary endpoint: Maximum Tolerated Dose of Bortezomib. Started Jan 2007; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00784823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784823.